Log in to search using one of your social media accounts:

 

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease
(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Bristol-Myers Squibb ’s Orencia for active psoriatic arthritis
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb ’s Orencia for the treatment of adult patients with active psoriatic arthritis (PsA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb ’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 6, 2017 Category: Drugs & Pharmacology Source Type: news

Bristol-Myers Squibb launches prefilled syringe option for arthritis drug
Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old. The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home. Get the full story at our sister site, Drug Delivery Business News. The post Bristol-Myers Squibb launches prefilled syringe option for arthritis drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pediatrics Pharmaceuticals Wall Street Beat Bristol-Myers Squibb Co. Source Type: news

Abatacept Helps Joints in Psoriatic Arthritis (CME/CE)
(MedPage Today) -- Benefits were less for skin manifestations (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 7, 2017 Category: Dermatology Source Type: news

Orencia (Abatacept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 17, 2017 Category: Drugs & Pharmacology Source Type: news

Common Drugs Boost Diabetes Risk in RA Patients (CME/CE)
(MedPage Today) -- Hydrochloroquine, abatacept associated with reduced risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 25, 2016 Category: Cardiology Source Type: news

US as a Marker of Early Response to Abatacept in RA US as a Marker of Early Response to Abatacept in RA
Ultrasound can play an important role in assessing the early efficacy of abatacept among biologic-naive rheumatoid arthritis patients.Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA
Abatacept is indicated in combination with methotrexate for adults with highly active or progressive RA who have not previously been treated with methotrexate.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 6, 2016 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Abatacept fails to provide benefit in relapsing-remitting MS
Results from the double-blind, randomized, placebo-controlled phase II ACCLAIM study indicate that abatacept has no effect on reducing the number of new gadolinium-enhancing lesions on MRI in... (Source: Clinical Neurology News)
Source: Clinical Neurology News - August 2, 2016 Category: Neurology Source Type: news

CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA
The EMA's Committee for Medicinal Products for Human Use recommended marketing authorization for abatacept in combination with methotrexate for methotrexate-naive adults with rheumatoid arthritis. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Bristol-Myers Squibb launches Orencia ClickJect drug-device combo for rheumatoid arthritis
Bristol-Myers Squibb said today it launched the Orencia ClickJect autoinjector designed for the self-administration of Orencia to treat moderate to severe rheumatoid arthritis. The Orencia ClickJect is designed to deliver 125 mg of subcutaneous Orencia through a push button operation with injection confirmation to reduce the possibility of user errors, the company said. “Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector....
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Bristol-Myers Squibb Co. Source Type: news

Abatacept Monotherapy vs Abatacept Plus DMARDs in RAAbatacept Monotherapy vs Abatacept Plus DMARDs in RA
What benefits do the addition of DMARDs to abatacept therapy offer patients with rheumatoid arthritis? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Hydroxychloroquine, abatacept linked with reduced type 2 diabetes
LONDON – U.S. rheumatoid arthritis patients had a significantly reduced incidence of type 2 diabetes when on treatment with either hydroxychloroquine or abatacept in an analysis of more than 13,000... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 10, 2016 Category: Endocrinology Source Type: news

IV to SC Switch OK for Orencia in RA (CME/CE)
(MedPage Today) -- Going on vacation and don't want to bring meds along? (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 23, 2016 Category: Geriatrics Source Type: news

Monotherapy an Option in RA With Orencia (CME/CE)
(MedPage Today) -- Suitable for patients who can't tolerate methotrexate (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 14, 2016 Category: Geriatrics Source Type: news

Orencia: Try Again in Lupus? (CME/CE)
(MedPage Today) -- Benefits seen for articular symptoms (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 31, 2016 Category: Primary Care Source Type: news

Sustaining Remission After RA Therapy Ends Sustaining Remission After RA Therapy Ends
Dr Deane discusses results from a randomized trial evaluating maintenance of remission after rapid withdrawal of abatacept and methotrexate--alone or in combination. Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2016 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

Antibodies Predict RA Response to Orencia (CME/CE)
(MedPage Today) -- Patients seropositive for rheumatoid factor or ACPA less likely to stop abatacept (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 8, 2016 Category: Geriatrics Source Type: news

Review Shows Varying Safety of Rheum Biologics (CME/CE)
(MedPage Today) -- Results generally favor Orencia and others over Remicade in autoimmune disorders (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - December 23, 2015 Category: Geriatrics Source Type: news

Orencia Does Not Ruin Pneumonia Vax Efficacy (CME/CE)
(MedPage Today) -- Abatacept suppresses immune response a bit, but vaccine should still work (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 18, 2015 Category: Rheumatology Source Type: news

Orencia Safe in RA, Even With HBV (CME/CE)
(MedPage Today) -- An Italian study found no cases of viral reactivation over 2 years (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 20, 2015 Category: Geriatrics Source Type: news

Antibodies and RA Treatment: Is There a Link? (CME/CE)
(MedPage Today) -- Anti-citrullinated protein antibodies levels predicted response with Orencia, but not Humira (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 15, 2015 Category: Geriatrics Source Type: news

Orencia, Actemra Comparable for RA Treatment (CME/CE)
(MedPage Today) -- Similar efficacy, but baseline predictors of response differed (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 11, 2015 Category: Geriatrics Source Type: news

Abatacept Might Be First-Ever Treatment for Rare Immune DeficiencyAbatacept Might Be First-Ever Treatment for Rare Immune Deficiency
Some devastating aspects of common variable immune deficiency are a result of a defect in trafficking of the immune down-regulator CTLA4, which can be overcome by treatment with abatacept. Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2015 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news

Abatacept Safety, Efficacy Maintained in JIA (CME/CE)
(MedPage Today) -- Phase III study reports reduction of adverse events with long-term use (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 29, 2015 Category: Geriatrics Source Type: news

Rituxan Cost-Effective Choice After TFN Inhibitors Fail (CME/CE)
(MedPage Today) -- For RA patients, rituximab is equivalent to IV abatacept in safety and efficacy (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 4, 2015 Category: Primary Care Source Type: news

RA: Infection Risk Lower With Enbrel or Orencia (CME/CE)
(MedPage Today) -- Studies are needed to balance harms and benefits of different biologics in individual patients. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 26, 2015 Category: Consumer Health News Source Type: news

abatacept, Orencia
Title: abatacept, OrenciaCategory: MedicationsCreated: 2/8/2006 12:00:00 AMLast Editorial Review: 4/7/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - April 7, 2015 Category: Drugs & Pharmacology Source Type: news

RA Remission May Hold Steady After Stopping Abatacept (CME/CE)
(MedPage Today) -- Remission predicted by HAQ-DI score or C-reactive protein at baseline. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 3, 2015 Category: Geriatrics Source Type: news

Evaluating Drug-free Remission With Abatacept in Early RAEvaluating Drug-free Remission With Abatacept in Early RA
Does the addition of abatacept to MTX therapy help achieve drug-free remission in early rheumatoid arthritis? Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 17, 2015 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Lower Maintenance Abatacept Dose Maintains RA Remissions (CME/CE)
(MedPage Today) -- Even half doses help RA patients maintain reduced disease activity (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - January 16, 2015 Category: Geriatrics Source Type: news

Psoriatic Arthritis: Biomarkers May Predict Drug Response Psoriatic Arthritis: Biomarkers May Predict Drug Response
A 1-step test of 57 synovial tissue proteins may predict which patients with psoriatic arthritis would benefit from adalimumab or abatacept. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Durable Drug-Free Remission Possible for RADurable Drug-Free Remission Possible for RA
Some adults with active rheumatoid arthritis (RA) achieved drug-free remission at 12 months after first-line treatment with abatacept, and a proportion remained drug-free up to 18 months. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Orencia Combo Tops in Early, Severe RA
PARIS (MedPage Today) -- In a study of patients with poor-prognosis early rheumatoid arthritis, more patients treated with abatacept (Orencia) plus methotrexate were in remission at 1 year than were those on methotrexate alone, a researcher reported here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 12, 2014 Category: Geriatrics Source Type: news

Effectiveness of Abatacept for RA in Europe and CanadaEffectiveness of Abatacept for RA in Europe and Canada
IV abatacept may be a safe and effective therapeutic option for patients with moderate-to-severe rheumatoid arthritis. BMC Musculoskeletal Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2014 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Orencia Aids Beta Cell Function (CME/CE)
(MedPage Today) -- Immune modulation with abatacept (Orencia) helped slow the decline of beta cell function in patients with recent-onset type 1 diabetes even after the treatment stopped, researchers reported. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 4, 2013 Category: Endocrinology Source Type: news

Orencia Slows Proteinuria in Renal Disease (CME/CE)
ATLANTA (MedPage Today) -- Proteinuria resolved partly or completely in a small group of patients with focal segmental glomerulosclerosis treated with abatacept, according to a study reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 9, 2013 Category: Primary Care Source Type: news

Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease
(American Society of Nephrology) An investigational drug called ZS-9 demonstrated promising Phase 2 clinical trial results for treating abnormally high potassium levels in patients with chronic kidney disease.The immune drug abatacept did not provide benefits above standard treatment for patients with kidney inflammation caused by lupus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2013 Category: Global & Universal Source Type: news

Arthritis Drug Could Benefit Some Kidney Disease Patients
Orencia may help treat a form of kidney disease that often leads to organ failure, study suggests Source: HealthDay Related MedlinePlus Pages: Kidney Diseases, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 8, 2013 Category: Consumer Health News Source Type: news

Repurposed drug may be first targeted treatment for serious kidney disease
(Massachusetts General Hospital) A team led by Massachusetts General Hospital researchers is reporting that treatment with abatacept appeared to halt the course of focal segmental glomerulosclerosis in five patients, preventing four from losing transplanted kidneys and achieving disease remission in the fifth. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2013 Category: Global & Universal Source Type: news

SMC recommendation of self-injection formulation of abatacept
The Scottish Medicines Consortium (SMC) has announced that abatacept solution for subcutaneous injection (Orencia® SC) has been accepted for use within NHS Scotland, in combination with methotrexate (MTX), as a first-line biologic agent for adults with severe rheumatoid arthritis (RA), after failure with conventional disease modifying anti-rheumatic drugs (DMARDs). (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 13, 2013 Category: Drugs & Pharmacology Source Type: news

Abatacept, Adalimumab Equal Head-to-Head for RA at 2 YearsAbatacept, Adalimumab Equal Head-to-Head for RA at 2 Years
The first head-to-head comparison of 2 biologics showed comparable efficacy for the 2 commonly used drugs. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
PRINCETON, N.J. & NANJING, China--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Simcere Pharmaceutical Group (SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic... BiopharmaceuticalsBristol-Myers Squibb, Simcere Pharmaceutical, Orencia, abatacept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2013 Category: Pharmaceuticals Source Type: news

In Rheumatoid Arthritis, Abatacept As Effective As Adalimumab, With Fewer Injection Site Reactions
Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA). AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2013 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

ORENCIA® shows comparable efficacy to Humira®
Bristol-Myers Squibb Company (NYSE: BMY) has announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the safety and efficacy of the subcutaneous (SC) formulation of abatacept versus adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 12, 2013 Category: Drugs & Pharmacology Source Type: news

Abatacept as effective as adalimumab in rheumatoid arthritis
(European League Against Rheumatism) Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept and adalimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2013 Category: Global & Universal Source Type: news

Low Antibody Response Seen With RA Drug (CME/CE)
(MedPage Today) -- Few rheumatoid arthritis patients treated with abatacept (Orencia) developed immunogenic responses that could interfere with efficacy and safety of the biologic agent, an international study found. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 1, 2013 Category: Geriatrics Source Type: news

SMC recommends abatacept
The Scottish Medicines Consortium (SMC) has announced today that abatacept (Orencia®) has been accepted for use within NHS Scotland, in combination with methotrexate (MTX), as a first-line biologic agent for adults with rheumatoid arthritis (RA), after failure with two conventional DMARDs. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 8, 2013 Category: Drugs & Pharmacology Source Type: news

Abatacept Use After Failure of Multiple Biologics in RAAbatacept Use After Failure of Multiple Biologics in RA
How safe and effective is abatacept in treating RA patients who have failed multiple therapies? Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 20, 2013 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news